Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
edit · stock forecast · 25 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 25 Wall Street analysts in the past 3 months
Buy
25 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$5.00
+88.3% upside
Low
$4.00
Median: $5 · Last Close: $2.65
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$5.00
88.3% upside
High Target
$6
126.0%
Low Target
$4
50.7%
Current Price
$2.65
as of today
Based on analyst price targets, the EDIT stock price prediction for the next 12 months ranges from $4 to $6. The consensus EDIT price forecast of $5.00 implies 88.3% upside from the current price of $2.65.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.59 | ↓ 2.50% |
1-day model range: $2.51–$2.66. Peak: $2.66 (-2.50%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -25.3% |
| 2028 | — | -34.7% |
| 2029 | — | -38.9% |
| 2030 | — | -40.8% |
| 2031 | — | -41.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · EDIT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-05 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-10 | Jones Trading | Upgrade ↑ | Hold→Buy |
| 2026-03-09 | Chardan Capital | Maintains | Buy→Buy |
| 2025-09-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-03 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-13 | Baird | Maintains | Outperform→Outperform |
| 2025-05-13 | Baird | Maintains | Outperform→Outperform |
| 2024-12-16 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2024-12-16 | Evercore ISI Group | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Editas Medicine, Inc. (EDIT) stock. Of the recent 127 rating actions, 13 were upgrades and 11 were downgrades. 25 analysts currently cover EDIT.
Analyst Recommendation Trends
EDIT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$15M
↑ 95.4% YoY
Revenue Next Year
$13M
↓ 8.9% YoY
EPS This Year
$-1.01
EPS Next Year
$-0.97
↓ 4.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast EDIT EPS of $-1.01 for the current fiscal year, based on estimates from 8 analysts. The EDIT revenue forecast is $15M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The EDIT stock forecast is supported by two independent data sources: analyst consensus ratings from 25 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus EDIT price target is $5.00 (+88.3% upside), with an analyst consensus of Buy.
The EDIT short-term stock prediction for tomorrow is $2.59 (-2.50%). The EDIT stock prediction for 2030 projects a range of $1–$2.
Editas Medicine, Inc. trades on NASDAQ under the ticker EDIT. The EDIT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 56% of covering analysts.
Frequently asked questions
EDIT forecast · 8 questionsAccording to 25 Wall Street analysts, the average 12-month EDIT price target is $5.00, with a high forecast of $6.00 and a low of $4.00. The median price target is shown in the chart above when available. This implies +88.3% potential upside from the current price of $2.65.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.